LOS ANGELES, CA / ACCESSWIRE / December 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...
LOS ANGELES, CA / ACCESSWIRE / December 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 19.40% ...
Humacyte, Inc. (HUMA) Securities Class Action: The lawsuit claims that Humacyte and certain of its executives failed to disclose material adverse facts about the company’s business, operations ...
DURHAM, N.C., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable ...
Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has be ...
On Friday, Humacyte Inc (HUMA) stock saw a modest uptick, ending the day at $4.47 which represents a slight increase of $0.07 or 1.59% from the prior close of $4.4. The stock opened at $4.44 and ...
Humacyte, Inc. (NASDAQ:HUMA – Get Free Report) has been assigned a consensus rating of “Buy” from the eight research firms ...
Shareholders accuse Humacyte of misleading investors about quality issues. STORY HIGHLIGHTS Shareholders accuse Humacyte of misleading investors about quality issues. Humacyte's stock fell after ...
SAN FRANCISCO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ: HUMA) and certain of its executives are now defendants in a class action lawsuit filed in the U.S. District Court for the ...
Insider activity at Humacyte (HUMA) has drawn attention after a 17% drop in the company’s stock price over the past year. Insiders, including founder Laura Niklason and board member Gordon ...
SAN DIEGO, Nov. 24, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Humacyte ...